Compare · DXCM vs MDLN
DXCM vs MDLN
Side-by-side comparison of DexCom Inc. (DXCM) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $42.58B, about 1.3x DXCM ($31.89B).
- Over the past year, DXCM is up 11.2% and MDLN is down 20.5% - DXCM leads by 31.8 points.
- DXCM has been more active in the news (12 items in the past 4 weeks vs 4 for MDLN).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Medline Inc.
- Price
- $84.52+0.74%
- $32.38-4.86%
- Market cap
- $31.89B
- $42.58B
- 1M return
- -5.61%
- -7.54%
- 1Y return
- +11.24%
- -20.53%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Director Boehnlein Glenn S was granted 5,841 shares (SEC Form 4)
- New insider Boehnlein Glenn S claimed ownership of 42 shares (SEC Form 3)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Appoints Glenn Boehnlein to Board of Directors
- Dexcom Announces Upcoming Conference Presentation
- EVP Chief People & Culture Off Stern Sadie sold $226,669 worth of shares (2,565 units at $88.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 126,043 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
Latest MDLN
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.